$18MSeries B, 30 June 2025
Funds to bring its first FDA-labeled allogeneic stem cell therapy for cats to market.
- Amount
- $18M
- Stage
- Series B
- Announced
- 30 June 2025
- Lead
- Digitalis Ventures
- Other investors
- BOLD Capital, Hill Creek Partners, NovaQuest Capital
- Use of funds
- Funds to bring its first FDA-labeled allogeneic stem cell therapy for cats to market.
- Checked
- Announced by the company
- Source
- Gallant raises $18M Series B gallant.com